VCNX News and Press, Vaccinex Inc. From 09/22/20

Gainers: NanoVibronix (NAOV) +98%, AIM ImmunoTech (AIM) +29%, Rockwell Medical (RMTI) +22%, Aurora Cannabis (ACB) +16%, Allied Healthcare Products (AHPI) +15%.Losers: Vaccinex (VCNX) -56%, BioSig Technologies (BSGM) -30%, ADC Therape...

Gainers: NanoVibronix (NAOV) +106%.Carvana (CVNA) +33%.AIM ImmunoTech (AIM) +25%.GameStop (GME) +21%.Boxlight (BOXL) +20%.Rockwell Medical (RMTI) +20%.Blink Charging (BLNK) +19%.Natural Alternatives International (NAII) +18%.Issuer Direct (ISDR) +17%.Renren (RENN) +16%.Losers:&...

Results from the early manifest treatment arm (cohort B1, N=179) in a Phase 2 clinical trial, SIGNAL, evaluating Vaccinex's (VCNX) lead candidate pepinemab in early manifest and prodromal Huntington's disease ((HD)) patients failed to meet expectations.Specifically, pepinemab failed to suffic...

Vaccinex (VCNX) has reported topline results from the early manifest treatment arm (Cohort B1, N=179) of the Phase 2 SIGNAL trial of its lead candidate, pepinemab, in patients with early manifest and prodromal Huntington’s disease ((HD)). The study had two co-primary endpoints, a ...

K ey cognitive endpoint s trending towards but did not reach statistical significance in early manifest population . O verall study does not meet pre-specified co- primary endpoints Results support continued development in Alzh...

Vaccinex (NASDAQ: VCNX )   jumps 11%  premarket on heels of a clinical collaboration agreement with Merck (NYSE: MRK )  to evaluate the combination of company's investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab)...

Sorrento Therapeutics (NASDAQ: SRNE )   +30%  on FDA nod for early-stage COVID-19 antibody trial. More news on: Sorrento Therapeutics, Inc., Hepion Pharmaceuticals, Inc., Vaccinex, Inc., , Stocks on the move, Read more ...

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has entered into a clinical collab...

ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, announced the appointment of Robert Scala as Chief Commercial Officer....

Vaccinex (NASDAQ: VCNX ) : Q2 GAAP EPS of -$0.39 beats by $0.12 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...